Related Experiment Video
Updated: Jul 11, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study
Sylvia Feyler1, Andy Rawstron, Graham Jackson
1St. James University Hospital, Leeds, UK.
Abstract:
Thalidomide maintenance has unresolved issues regarding dosage and toxicity. We evaluated this in five dose cohorts in 100 patients. At a median follow-up of 32.3 months, 23 patients had stopped thalidomide for disease progression, 54 for side effects. 3-year overall and progression-free survival was 76% and 41% respectively. Dosage did not influence disease outcome but greatly affected toxicity. Fifteen patients converted from partial remission to complete remission on thalidomide at a median of 13.5 months. Maintenance doses >200 mg were largely unachievable and peripheral neuropathy was the main toxicity. Lower doses enabled more patients to stay on the drug for a useful period of time.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring: Drug Analysis Methods
